Cytiva Plus Cardiomyocytes are human embryonic stem cell (hESC) derived cardiomyocytes specifically designed for use in the integrated risk assessment of compounds for cardiotoxic responses. The cardiomyocytes form spontaneously beating monolayers when plated into microwell plates and exhibit the appropriate morphology and electrophysiological responses when treated with known compounds.
Cytiva Plus Cardiomyocytes have significant advantages over traditional cell and ex vivo animal models for drug safety assessment including the fact that they are of human origin and are produced in a way that recapitulates native human heart cell development, without engineering techniques that could alter expression levels of relevant genes.
When combined with platforms allowing multi-parametric analyses of both electrophysiological and structural responses to drugs, Cytiva Plus Cardiomyocytes have been shown to provide an integrated pre-clinical human model capable of surveying a wide range of cardiac liabilities and cardiotoxicity mechanisms. This is in marked contrast to the varied and significant limitations of the disparate model systems widely used today.
Features:
- Choice of quantities to match a range of applications.
- Suitable for MEA, high-content analysis (HCA), calcium transient measurements, impedance, and manual patch clamping.
- Ready to record, direct from thaw, after five to seven days incubation. No replating required.
- Display expected pharmacological responses to compounds.
- Display expected multi-electrode arrays (MEA) waveform and performance characteristics.
- Cryopreserved for ease of use.
Product Overview
